Laboratory testing plays a central role in the diagnosis, monitoring, and management of liver disease. Elevated serum transaminases—particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—are commonly used to screen for liver injury, identify the cellular site of damage, assess prognosis in chronic liver conditions, and monitor therapeutic response. However, no single test provides a complete diagnostic picture. Clinicians must interpret liver enzyme levels alongside other laboratory values, clinical history, and physical examination findings to form an accurate assessment.
ALT is a cytosolic enzyme found
predominantly in hepatocytes and is considered more specific for
liver injury than AST. Its longer plasma half-life (~24 hours)
makes it a reliable marker for ongoing hepatocellular damage. It
is released from damaged hepatocytes.
AST, by contrast, is present in both cytosolic and mitochondrial compartments and is found in multiple tissues including the heart, muscle, RBCs, WBCs, kidney, pancreas, and brain, making it less specific for liver pathology. Notably, a rise in AST can be an early sign of liver transplant rejection.
Alkaline phosphatase (ALP) is another key enzyme, found in various tissues including liver, bone, and placenta. In pediatric populations, elevated ALP may reflect bone growth or transient hyperphosphatemia of infancy rather than liver disease. However, in liver pathology, elevated ALP can indicate biliary epithelial damage, cirrhosis, or vitamin D deficiency-related osteopenia. Conversely, low ALP levels may suggest zinc deficiency or Wilson disease.
Gamma-glutamyl transpeptidase (GGT), though not liver-specific, is useful in distinguishing hepatic from bone-related causes of elevated ALP. GGT levels are highest in neonates and can be influenced by medications such as anticonvulsants. In certain pediatric liver disorders—like progressive familial intrahepatic cholestasis (PFIC 1& 2), BRIC, disorders of bile acid synthesis, and panhypopituitarism—GGT may be low or normal despite significant disease.
Direct (conjugated) bilirubin levels reflect hepatocyte dysfunction or biliary obstruction. Elevated levels are characteristic of conditions like Dubin-Johnson syndrome, where impaired transport of organic anions into bile canaliculi leads to bilirubin retention.
Beyond enzyme markers, liver function tests evaluate the
organ’s synthetic capabilities.
Albumin, synthesized exclusively by the
liver, serves as a marker for chronic liver disease when
low—assuming no confounding factors like malnutrition or protein
loss. Its long half-life (~20 days) makes it less useful for
detecting acute changes.
Prothrombin time (PT), a vitamin K–dependent measure,
reflects the liver’s ability to produce clotting factors.
Prolonged PT may indicate either vitamin K deficiency or
impaired hepatic synthesis, and is a sensitive marker for acute
liver failure.
Prothrombin Time (PT) and International Normalized Ratio (INR) are closely related tests used to assess blood clotting and liver synthetic function.
PT measures the time it takes for blood to clot, specifically evaluating the extrinsic and common coagulation pathways. It reflects the activity of clotting factors I (fibrinogen), II (prothrombin), V, VII, and X—all produced in the liver and dependent on vitamin K.
INR is a standardized version of PT that accounts for variations in testing reagents and methods across laboratories. It allows for consistent interpretation, especially important when monitoring patients on anticoagulants like warfarin.
The INR is calculated using the formula:
Where ISI is the International Sensitivity Index assigned to the thromboplastin reagent used.
In liver disease, both PT and INR can be prolonged due to
impaired synthesis of clotting factors, making them key
indicators of hepatic synthetic function and prognosis.
Viral hepatitis: A, B, C, D, E, and non-A–E variants
Other viruses: Cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza, adenovirus, herpes simplex virus (HSV), echovirus, enterovirus, coxsackievirus, parvovirus
α1-antitrypsin deficiency (A1AT)
Wilson disease
Iron storage disorders
Inborn errors of metabolism: fatty acid oxidation disorders, urea cycle disorders, galactosemia, hereditary fructose intolerance
Alagille syndrome
Cystic fibrosis
Tyrosinemia
Celiac disease
Autoimmune hepatitis (AIH)
Primary sclerosing cholangitis
Systemic lupus erythematosus (SLE)
Nonalcoholic fatty liver disease (NAFLD)
Glycogen storage disease
Niemann-Pick disease
Hemophagocytic lymphohistiocytosis (HLH)
Hepatic tumors
Hypoperfusion
Sepsis
Intra-abdominal hemorrhage
Viral-induced myositis
Muscular dystrophy
Various medications and toxins known to cause liver enzyme elevation
Trend over time is more prognostic than a single elevated value. A rapid drop in aminotransferases with rising bilirubin and coagulopathy may signal massive hepatic necrosis and poor prognosis.
Marked elevations (>1,000 IU) are typically seen in:
Acute viral hepatitis
Drug or toxin-induced liver injury
Ischemic hepatitis
Less commonly, autoimmune hepatitis
AST:ALT ratio interpretations (though less validated in children):
<1: Suggestive of nonalcoholic steatohepatitis
>2: alcoholic liver disease
Disproportionate AST elevation may indicate:
Hemolysis
Rhabdomyolysis
Myopathy
Myocardial injury
Recent intense physical activity
Macro-AST (AST bound to immunoglobulins → reduced clearance)
Elevated LDH: Suggests hemolysis, myopathy, cardiac disease, or renal infarct
Elevated CPK and aldolase: Points to myopathic origin
Post-transplant differential diagnosis includes:
Acute or chronic cellular rejection
De novo autoimmune hepatitis
Infection
Biliary complications
Vascular complications
Total and Direct (Conjugated) Bilirubin: Elevated direct bilirubin suggests cholestasis or hepatocellular dysfunction.
Indirect (Unconjugated) Bilirubin: May be elevated in hemolysis or Gilbert syndrome.
Useful in assessing cholestatic liver diseases and bile acid synthesis disorders.
Elevated levels may indicate impaired bile flow or metabolism.
Elevated in hepatic encephalopathy or urea cycle disorders.
Interpretation requires careful handling and rapid processing due to instability.
Elevated lactate may suggest mitochondrial disorders or hypoxic injury.
Lactate-to-pyruvate ratio helps differentiate metabolic causes.
Low ceruloplasmin and elevated free copper are diagnostic clues for Wilson disease.
24-hour urinary copper excretion may also be elevated.
Deficiency or abnormal variants (e.g., PiZZ) can cause neonatal cholestasis or chronic liver disease.
Includes serum ferritin, transferrin saturation, and total iron-binding capacity.
Elevated ferritin may suggest hemochromatosis or inflammation.
ANA, SMA, LKM-1, and LC-1: Useful in diagnosing autoimmune hepatitis.
pANCA: May be associated with primary sclerosing cholangitis.
Hepatitis A–E, CMV, EBV, HSV, and others.
PCR testing helps confirm active infection and monitor viral load.
Includes plasma amino acids, urine organic acids, and acylcarnitine profile.
Essential for detecting inborn errors of metabolism.
Hypothyroidism can present with elevated liver enzymes in infants.
Important to rule out endocrine causes of liver dysfunction.
Elevated IgG may support autoimmune hepatitis.
Low IgG or IgA may suggest immunodeficiency syndromes.
References:
Behrman, R. E., Kliegman, R. M., & Jenson, H. B. (Eds.). (2020). Nelson Textbook of Pediatrics (21st ed.). Elsevier.
American Academy of Pediatrics. (2021). Red Book: 2021 Report of the Committee on Infectious Diseases (32nd ed.). American Academy of Pediatrics.
Squires, R. H., & Alonso, E. M. (2020). Pediatric liver transplantation. In R. E. Behrman, R. M. Kliegman, & H. B. Jenson (Eds.), Nelson Textbook of Pediatrics (21st ed., pp. 1804–1812). Elsevier.
Balistreri, W. F. (2017). Pediatric hepatology: Current concepts and controversies. Journal of Pediatric Gastroenterology and Nutrition, 64(4), 451–456.
Sokol, R. J., & Narkewicz, M. R. (2015). Approach to the child with liver disease. In M. Feldman, L. S. Friedman, & L. J. Brandt (Eds.), Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (10th ed., pp. 1423–1438). Elsevier.
Centers for Disease Control and Prevention. (2023). Pediatric hepatitis: Clinical guidance and surveillance